SCHEMBL4786286

SCHEMBL4786286

O=S(=O)(Cl)Cl.c1ccc2onnc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 2/20 0.33
GAA P10253 2/20 0.33
ALOX15 P16050 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
MAOB P27338 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29815923 0.87
SCHEMBL35607 0.87
Fluoride SCHEMBL28572049 0.85 TSHR (0.36) ALDH1A1HSD17B10LMNAGAAMAPT
SCHEMBL5845408 0.85 TSHR (0.36) ALDH1A1HSD17B10LMNAGAAMAPT
Hydrogen Sulfide SCHEMBL29184289 0.85 TSHR (0.36) ALDH1A1HSD17B10LMNAGAAMAPT
Cyanide SCHEMBL1054825 0.81 PSMB8 (0.35) ALDH1A1LMNAGAAMAPTNPC1
Anthracene SCHEMBL22582076 0.78 MAPT (0.44) TDP1ALDH1A1HSD17B10LMNAGAA
Thiophene SCHEMBL17164528 0.76 NPC1 (0.31) ALDH1A1GAAMAPTNPC1RAB9A
Pyrene SCHEMBL18343598 0.74 ALDH1A1 (0.42) TDP1ALDH1A1HSD17B10LMNAGAA
SCHEMBL7838848 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP TDP1 2234/4885ALDH1A1 2627/4885HSD17B10 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.